13 July 2026    HARGREAVE HALE AIM VCT PLC (the “Company”) Offer Update – Extension of Closing Date and New Early Bird Offer On 23 January 2026, Hargreave Hale AIM VCT plc (the “Company”) launched an offer for subscription to raise up to £20 million together with the discretion to utilise an over-allotment facility to raise up to a further £10 million (the “Offer“). Full details of the Offer are contained in an offer document (the “Offer Document“), which is available on the Company’s website (www.hargreaveaimvcts.co.uk). The Offer Document has today been amended to extend the closing date for the Offer, as set out below, and to include certain updated financial information about the Company. Under the amended terms and conditions of the Offer, the Board has decided to extend the closing date for receipt of all Application...

Joshua HareJoshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, LongeveronPoster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed Using Free Water MRI” presented at July 13th In Person Poster Presentation Session Results support a clinically relevant and long-lasting anti-inflammatory mechanism of action of laromestrocel in gray and white matter of the brain, indicate potential blood biomarker correlates with clinical outcomes, and support continued clinical development of laromestrocel for Alzheimer’s disease Longeveron has received U.S. FDA RMAT designation for its Alzheimer’s disease program and has aligned on a Phase 3 study designMIAMI,...

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen’s novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region. Pursuant to the term sheet, under the license agreement, Ocugen is expected to receive upfront license fees and near-term development milestone...

No other intercept of comparable true thickness has returned as high a grade at Eau Claire to date TORONTO, July 13, 2026 (GLOBE NEWSWIRE) — Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to announce the second batch of assay results (8 holes, 5,064 metres (m)) from its ongoing Phase 2 (15,000–25,000-metre) drill program at the Eau Claire gold project (“Eau Claire” or the “Project”), and that it has mobilized a third diamond drill rig to the site. The Project is located in the Eeyou Istchee Territory in the James Bay Region of Northern Quebec. The most significant result from this batch of drilling is conversion drill hole 26EC-115, which tested an inferred portion of the mineral resource approximately 52 m down strike of drill hole 26EC-102...

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mg Study evaluated patients with chronic NIU-PS in the U.S. Most patients in the study were treated by retina specialists. Full results to be presented at an upcoming medical meetingPRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic...

Serstech has today received an order from its South Korean partner Young Jin Solutec Co. Ltd with a total value of 12.6 MSEK. The order consists of instruments and software and will be delivered and invoiced during the third quarter of 2026.For further information, please contact: Stefan Sandor, CEO, Serstech AB Phone: +46 739 606 067 Email: ss@serstech.com or Arve Nilsson, Chairman of the Board, Serstech AB Phone: +45 40 35 82 65 Email: arve.nilsson@serstech.com or visit: www.serstech.com This is information that Serstech AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 12:45 CET on July 13, 2026. Certified advisor to Serstech is Svensk Kapitalmarknadsgranskning AB (SKMG). About Serstech Serstech delivers...